Quantum Leap Healthcare Collaborative

Agent Information Sheet

Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for
Close
Close
I-SPY Trial Manuscript
<- Back to All Agents

ganetespib

Trade Name:
STA-9090
Status:
Stopped for Futility
Treatment Protocol:
Ganetespib is a Hsp90 inhibitor. Ganetespib was administered at 150 mg/m2 intravenously once every 3 weeks with Paclitaxel administered at 80 mg/m2 weekly for 12 total weeks. This regimen was followed by AC (q2w or q3w) for 4 weeks.
Date Entered I-SPY:
October 13, 2014
Date Left I-SPY:
October 3, 2015
No. Participants in Arm:
97
Graduating Subtypes:
Agent Description:

A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) . Ganetespib binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of "client" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors. Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.

Notes:
Final pCR Probabilities:
Primary Manuscript:
 
abstractpdfdoi link